The drugs company, Actelion, said on Thursday that its third quarter loss widened to SFr11.7 million ($6.6 million). Its losses for the same period in 1999 amounted to SFr3.5 million.
But the management said the figures were in line with expectations.
The company has yet to launch its first product. It expects to begin selling the hypertension drug, Tracleer, in the second half of next year pending approval from the United States Food and Drug Administration.
Actelion is listed on the high-tech SWX New Market and its management team is made up largely of former Roche employees.
swissinfo with agencies